← Leaderboards
William C Groutas
Wichita State University
$4,709,702
Attributed
$13,276,913
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,276,913 · 5
By mechanism
R01$12,889,548 · 4
R21$387,365 · 1
Top collaborators
- Kyeong-Ok Chang16 shared
- Stanley Perlman11 shared
- Terry L Bowlin5 shared
- Linda J. Saif5 shared
- Richard Arthur Calderone2 shared
- Yunjeong Kim2 shared
Others in their field
Top investigators on “Protease Inhibitor”
- Constance Ann Benson · University Of California, San Diego$150,461,206
- Robert Turner Schooley · University Of Colorado Denver$48,400,257
- John Damon Chodera · Sloan-Kettering Inst Can Research$40,777,114
- Daniel R Kuritzkes · Brigham And Women'S Hospital$26,572,064
- David Heimbrook · Leidos Biomedical Research, Inc.$26,054,235
- Celia A. Schiffer · Univ Of Massachusetts Med Sch Worcester$24,364,826
Research focus
Protease InhibitorIn VivoBiochemicalDesignPre-ClinicalLeadStructure-Activity RelationshipStructureEnzymesSeriesPharmaceutical PreparationsCellsPolyproteinsAnalogDrug CandidateViralPharmaceutical ChemistryVirusVirus ReplicationPeptide HydrolasesVaccinesIn VitroDisease OutbreaksBase
Grant awards (24)
Small Molecule Protease Inhibitors against MERS-CoV and Coronaviruses of Pandemic Potential$733,730
R01 · FY2025 · AI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$731,337
R01 · FY2025 · AI
Small Molecule Protease Inhibitors against MERS-CoV and Coronaviruses of Pandemic Potential$773,323
R01 · FY2024 · AI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$735,037
R01 · FY2023 · AI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$735,037
R01 · FY2022 · AI
Small Molecule Protease Inhibitors against MERS-CoV$728,584
R01 · FY2022 · AI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$774,037
R01 · FY2021 · AI
Small Molecule Protease Inhibitors against MERS-CoV$730,761
R01 · FY2021 · AI
Small Molecule Protease Inhibitors against MERS-CoV$732,873
R01 · FY2020 · AI
Small Molecule Protease Inhibitors against MERS-CoV$734,924
R01 · FY2019 · AI
Small Molecule Protease Inhibitors against MERS-CoV$775,916
R01 · FY2018 · AI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2018 · AI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2017 · AI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2016 · AI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2015 · AI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$784,022
R01 · FY2014 · AI
Novel antifungal therapeutics$167,965
R21 · FY2012 · AI
Novel antifungal therapeutics$219,400
R21 · FY2011 · AI
Inhibitors of Proteolytic Enzymes$180,660
R01 · FY2005 · HL
Inhibitors of Proteolytic Enzymes$180,660
R01 · FY2004 · HL
Inhibitors of Proteolytic Enzymes$178,820
R01 · FY2003 · HL
Inhibitors of Proteolytic Enzymes$174,220
R01 · FY2002 · HL
MECHANISM BASED INHIBITORS OF SERINE PROTEINASES$135,820
R01 · FY2001 · HL
MECHANISM BASED INHIBITORS OF SERINE PROTEINASES$132,607
R01 · FY2000 · HL